Competence Centre on Health Technologies
Follow us on

FAQ

Practical notes of beREADY test

beREADY test needs a small tissue sample that is taken from the uterus with a thin catheter.
Embryo transferring during the same menstrual cycle as beREADY testing, is not possible.
Tissue sampling procedure does not injure the uterus and the tissue regenerates in the next menstrual cycle.
beREADY test is validated for natural (LH) and hormone replace cycle (HRT).
Handling of personal data
All personal data is protected according to law and transferred to laboratory only via a safe digital website. No personal data or documents are attached with the shipment. The test results are uploaded to a secure online environment that your doctor has access to. The patient may request the doctor for a printed copy of the beREADY report, which includes all relevant treatment and tissue sampling taking time information.

General questions about beREADY test

Does the beREADY test guarantee a pregnancy? 
Failure of embryo implantation can be caused by other reasons, like embryo quality. Due to that reason the beREADY test cannot guarantee you a pregnancy, but it does give your doctor a guidance of how to personalize your IFV treatment if you have displaced WOI and increases your chances of getting pregnant. Our experience shows that many women with previous implantation failure become pregnant after using the beREADY test in their personalised treatment plan.
What kind of sample is needed for the test?
beREADY test needs a small endometrial tissue sample that is taken from the uterus with a thin catheter. Tissue sampling procedure does not injure the uterus and the tissue is fully regenerated in the next menstrual cycle.
Does re-sampling cost?
beREADY test report can recommend a re-biopsy to confirm that the optimal WOI is achieved. To be sure that your personalised treatment plan is effective, one repetition of the sample analysis is free-of-charge.
How quickly do I receive results?
The test results are sent to your doctor within 14 working days after beREADY laboratory has received your sample. The average laboratory turnaround time is 6-8 working days. Usually results are received early enough to modify treatment plan already in the following IVF cycle. Embryo transfer during the same menstrual cycle as taking the beREADY test, is not possible.
My personal WOI is significantly shifted. What next?
Your doctor will modify your treatment plan according to the recommendation sent by the beREADY laboratory. If re-sampling during next cycle is recommended, you will be suggested to give a new biopsy. This will confirm that a receptive endometrium and optimal WOI is achieved with the new treatment plan. One re-biopsy is free of charge.
What are the marker genes that beREADY test analyses? 
beREADY test evaluates 67 genes that are all involved in endometrial growth, maturation and receptivity. These genes characterize the readiness of your endometrium for embryo implantation. We have seen in our research that these 67 genes are enough and analysing any more genes does not make the test more accurate.
I don’t see a clinic near my home? Where can I take the test?
If the clinic, where your treatment takes place is not yet part of our network, please let us know and we will find the closest available location for your test or form a partnership with your clinic.
How is my personal health data protected?
All personal data is protected according to law and transferred to laboratory only via a secure website. No personal data or documents are attached with the shipment. The test results are uploaded to a secure website that your doctor can access. The patient may request the doctor for a printed copy of the beREADY report, which includes all relevant treatment and tissue sampling information.
What is the scientific evidence behind the beREADY test?

Our researchers have published several peer-revewed articles about the technology that is used for the beREADY analysis, about the biomarkers, data analysis and demonstration with patient samples:

 
Saare et al., A molecular tool for menstrual cycle phase dating in endometriosis transcriptomic studies. 2019, Biology of Reproduction, PubMed ID 31004479. Link to original study
 
Teder et al., TAC-seq: targeted DNA and RNA sequencing for precise biomarker molecule counting. 2018, npj Genomic Medicine, PubMed ID 30588329. Link to original study
 
Suhorutshenko et al., Endometrial receptivity revisited: endometrial transcriptome adjusted for tissue cellular heterogeneity. 2018, Human Reproduction, PubMed ID 30295736.  Link to original study
 
Altmäe et al., Meta-signature of human endometrial receptivity: a meta-analysis and validation study of transcriptomic biomarkers. 2017, Scientific Reports, PubMed ID 28855728.   Link to original study
 
Krjutškov et al., Single-cell transcriptome analysis of endometrial tissue. 2016, Human Reproduction, PubMed ID 26874359   Link to original study